PDS Biotechnology Corp — Director's Dealing 2019

Mar 26, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PDS Biotechnology Corp (PDSB)
CIK: 0001472091
Period of Report: 2019-03-15

Reporting Person: CONN GREGORY (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	115545	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$6.87	2026-01-31	Common Stock (17764)		Direct
Employee Stock Option (Right to Buy)	$15.33	2028-07-06	Common Stock (14450)		Direct
Employee Stock Option (Right to Buy)	$9.04	2029-03-14	Common Stock (44871)		Direct

Footnotes

F1: Stock Option fully vested in accordance with its terms.

F2: All unvested outstanding options of PDS Biotechnology Corporation were accelerated upon the effectiveness of the merger between Edge Therapeutics, Inc. and PDS Biotechnology Corporation and therefore the Stock Option is fully vested and immediately exercisable.

F3: Stock Option was fully vested on the date of grant.